Abstract: The present invention relates to a hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide. The hybrid anticancer prodrug according to the present invention sequentially releases quinone methide and cinnamaldehyde by H2O2 and acidic pH, and thus alkylates antioxidant GSH through the release of quinone methide, thereby inhibiting an antioxidative system and increasing oxidation stress, and generates and accumulates reactive oxygen species (ROS) through the release of cinnamaldehyde, thereby promoting apoptosis, and thus the hybrid anticancer prodrug according to the present invention can be favorably used as an anticancer drug by creating a synergetic anticancer effect through double stimulus-response and sequential treatment action in a cancer cell-specific manner.

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Abstract: The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.

Abstract: Provided herein are aptamers and pharmaceutical compositions comprising the same. In some embodiments, the aptamer selectively binds a protein of interest such as an extracellular receptor protein of interest (e.g., a cancer cell extracellular receptor protein, which may be differentially expressed in some embodiments). In some embodiments, the aptamer is directly linked by covalent bonding (e.g., via a geminal diamine linkage) to from 2 to 10 toxin compounds. Also provided herein is a method of selecting an aptamer that specifically binds to a protein expressed by a cell of interest, wherein in some embodiments the aptamer comprises at least one binding site for one or more active compounds. In some embodiments, primer regions flanking the variable region of the aptamers in the pool contains from 1 to 10 mismatches with respect to said forward or reverse primer.

Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.

Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

Abstract: Disclosed herein are auristatin-antibody conjugates and compositions thereof. The auristatin-antibody conjugates and compositions may be used for treating diseases such as cancer. Also disclosed are methods of producing auristatin-antibody conjugates.

Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

Abstract: The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.

Abstract: The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.

Abstract: The invention relates to a water-based biocompatible non-cytotoxic preparation for the selective staining of internal limiting membrane (ILM) and/or epiretinal membranes (ERM) in the human or animal eye, and to a kit containing said water-based preparation according to the invention.

Abstract: Polymeric systems useful for theranostic applications are disclosed. The polymeric systems comprise a fluorescent or fluorogenic moiety and a therapeutically active agent, each attached to the same or different polymeric moiety. The polymeric systems are designed such that a fluorescent signal is generated in response to a chemical event, preferably upon contacting an analyte (e.g., an enzyme) that is over-expressed in a diseased tissue or organ. Probes useful for inclusion in such polymeric systems, processes of preparing such probes and the polymeric systems, and uses thereof in diagnostic and/or theranostic applications are also disclosed.

Abstract: The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses.

Abstract: Dendronized metallic oxide nanoparticles, a process for preparing the same and their uses.

Abstract: The present invention relates to maltol-coated magnetite nanoparticles, pharmaceutical compositions comprising same, and methods for using same as contrast agents in magnetic resonance imaging.

Abstract: An in-vivo intravascular blood replacing liquid of the present invention is injected into a blood vessel to replace blood at an intravascular portion to be inspected therewith in making an in-vivo intravascular inspection. The blood replacing liquid comprises an aqueous medium unharmful for a living body and a gelling property imparting substance, unharmful for the living body, which is added to the aqueous medium to impart a gelling property to the blood replacing liquid. The blood replacing liquid has a viscosity of not more than 3 mPa·s when the blood replacing liquid is injected into the blood vessel.

Abstract: Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.

Abstract: The present invention discloses a method and corresponding apparatus utilizing UV-A and UV-C for treatment of textile materials. The method comprises the steps of (a) exposing incoming textile materials to UV-A radiation for detection of optically brightened textile materials and/or synthetic fiber materials; (b) separating detected optically brightened textile materials and/or synthetic fiber materials from the incoming textile materials; (c) exposing the separated incoming textile materials to UV-C radiation for sterilization and surface modification of the textile materials to increase wettability and absorbability and reduce pilling. The apparatus comprises an enclosed segregation chamber disposed with a cascading conveying means, a UV-A radiation source and an optically brightened textile materials and/or synthetic fiber materials separating means therewithin, and an enclosed segregation chamber disposed with a UV-C radiation source therewithin.

Abstract: A LED structure, a lighting fixture and a method of providing white light illumination. The LED structure comprises a substrate; a light emitting area defined on the substrate as a cavity; a first type of light emitting semiconductor source with bactericidal characteristics mounted in the cavity; a second type of light emitting semiconductor source mounted in the cavity with ability to excite the wavelength conversion material to generate white light; and a wavelength conversion material layer formed on top of the light emitting semiconductor sources. The invention enables disinfection by a lighting source or a luminaire visibly apparent to human as a white light source that is neither harmful to a human nor creates discomfort.

Abstract: The present invention relates to a vacuum exhaust system of a sterilizer, comprising: a sterilization chamber; a first vacuum pump connected to one side of the sterilization chamber; an oil mist trap section for exhausting steam incoming from the sterilization chamber via the first vacuum pump; and a second vacuum pump connected to the first vacuum pump and the oil mist trap section. The vacuum exhaust system of a sterilizer according to the present invention comprises the second vacuum pump connected to the first vacuum pump and the oil mist trap section, wherein by turning the second vacuum pump on to apply a vacuum to the operating oil in the first vacuum pump, thereby providing a certain pressure for evaporating water in liquid state to the first vacuum pump, the present invention can vaporize the water vapor trapped in the operating oil in the first vacuum pump.

Abstract: [Problem] Provided is a decontamination system which does not require large scale equipment such as large diameter ducts or anti-condensation heaters, while enabling, with respect to a plurality of rooms targeted to be decontaminated, pipelining of which distance is long for each room, the decontamination system being capable of supplying an accurate amount of decontamination gas for each room. [Solving Means] Compressed air-generating means and decontamination solution-supplying means are included, mixed gas-liquid adjusters and gas generators are respectively provided in each room targeted to be decontaminated, and a conveyance distance of gas-liquid supplying pipes which communicate with the mixed gas-liquid adjusters and the gas generators is longer than a conveyance distance of decontamination solution supplying pipes which communicate with decontamination solution-supplying means and the mixed gas-liquid adjusters.

Abstract: The present invention is directed to an autonomously powered vapor dispensing device comprising an intermediate basin which allows the volatile liquid contained therein to impregnate a dispensing material by capillarity and dispense into the atmosphere; and a heating element which heats the intermediate basin comprising the volatile liquid to force evaporation cyclically of the volatile liquid directly from the intermediate basin.

Abstract: Glass-based particles of a biocompatible material which comprises 40 to about 80 wt % borate (B2O3) intermixed into a carrier which is an ointment, cream, or surgical glue.

Abstract: A hydrogel based on a cross-linked ?-polyglutamic acid and ?-polylysine polymer is obtained by cross-linking of ?-polyglutamic acid with ?-polylysine, and it is a polymer having the following constitutional unit, wherein, m is a natural number of 15 to 45, n is a natural number of 3900 to 17000, and x is a natural number of 5 to 40. It also discloses a preparation method of as-described hydrogel and its application in preparation as a medical wound dressing.

Abstract: The subject matter of the present invention is a photopolymerizable liquid composition comprising at least one epoxidized polybutadiene prepolymer, at least one cationic photoinitiator, and at least one thioxanthone-derived photosensitizer, which can, for example, be in the form of a liquid dressing. The subject matter of the invention is also a process for obtaining a polymerized film from said photopolymerizable liquid composition, characterized in that said composition is applied to tissues such as the skin, the skin appendages or the mucous membranes so as to form a uniform liquid film, and the film thus obtained is subjected to ultraviolet radiation, preferably ultraviolet-visible radiation having a wavelength of between 380 and 405 nm, preferably between 385 and 395 nm.

Abstract: A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

Abstract: A heart valve is at least partially constructed from a block-copolymer, the block-copolymer having a phase structure formed by its constituent blocks, and wherein the phase structure is arranged so as to produce anisotropic physical properties in the heart valve.

Abstract: The invention provides a novel approach to controlled delivery of biomolecules (e.g., lipids and proteins) by employing novel amphiphilic polymers that are effective delivery vehicles. These unique amphiphilic polymers may be employed as controlled delivery vehicles or tissue engineering scaffolds wherein the delivery of lipophilic or amphiphilic bioactive molecules can be achieved. An amphiphilic biodegradable polymer platform is disclosed herein for the stable encapsulation and sustained release of biomolecules, such as S1P.

Abstract: The invention relates to magnesium-polymer composites, methods for their preparation and applications for their use. The composites include a combination of magnesium particles and polymer matrix. The polymer can include, but is not limited to, poly(lactic co-glycolic) acid. In certain embodiments, the composites of the invention are particularly useful for forming medical devices for implantation into a body of a patient. In certain other embodiments, the magnesium-polymer composites are useful for wound healing compositions for administration to an exterior surface of a body of a patient.

Abstract: The present disclosure relates to methods for stimulating collagen synthesis, cosmetic enhancement of soft tissue and/or inhibiting or treating scarring comprising administering a composition to an area to be treated within a soft tissue, wherein the composition comprises a tissue filler medium and a fluorophore; and illuminating the area with light having a wavelength which can be absorbed by the fluorophore.

Abstract: The implantable scaffold matrix composition for osteogenic regeneration has a biodegradable polymer material selected from the group consisting of one or more of polylactic acid, polyglycolic acid, or polycaprolactone, or any combination thereof to provide a time release delivery of an osteogenic effect and further has a pharmaceutical composition selected from the group consisting of one or more of ibuprofen, non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen, or naproxen sodium or any combination thereof and wherein the implantable composition has a primary and a secondary time release. The primary time release being one of the polymer compositions; each time release extending occurring between 0 days and 19 days, both not being at 0 days.

Abstract: A resorbable device for the reconstruction of cartilage includes a piece of fabric made of PGA, which can be impregnated with patient blood and fixable to a bone at an articulation, the piece preferably being impregnated with collagen.

Abstract: Compositions of P4HB with high purity have been developed. The compositions are prepared by washing P4HB biomass prior to solvent extraction, and precipitating P4HB from solution. The same solvent is preferably used to wash the P4HB biomass, and as a non-solvent to precipitate the polymer from a P4HB solvent solution. The highly pure P4HB compositions are suitable for preparing implants. The implants may be used for the repair of soft and hard tissues.

Abstract: According to the invention there is provided inter alia an implantable medical device with coatings comprising an immobilized heparin moiety and elutable paclitaxel and to methods for making such devices.

Abstract: A medical suction system and method of use is disclosed. The system may include a tube and a collection container. A distal portion of the tube may have a plurality of apertures that are disposed within the patient of an opening adjacent to an incision at a surgical site. A proximal portion of the tube extends out of the opening and is connected to the collection container. The opening is sealed around the tube so as to form a closed system with the collection container. The collection container may be resilient and form a vacuum by compressing by allowing the collection container to decompress. The collection container may also be provided to the user pre-compressed by rolling up the collection container and placing a band or wrapper around the compressed collection container. Alternatively, the collection container may be provided in the uncompressed state. Anchor tabs are used to secure the tube so that the plurality of apertures remain within the patient.

Abstract: A surgical suction device that uses positive pressure gas is shown and described. The surgical suction device includes an air amplifier. The air amplifier includes a structure defining a generally cylindrical cavity having a first opening at a first end and a second opening at a second end. The cylindrical cavity is defined by an inner wall of the cavity. The air amplifier includes an annular opening in the inner wall near the first end. The annular opening defines a jet opening adapted to allow a pressurized gas to flow out of the annular opening such that a low pressure region is produced at the first end and an amplified flow is produced at the second end. The annular opening is further configured such that the pressurized gas enters the cavity at an angle with respect to the inner wall of the cavity that is towards the second end.

Abstract: A wound dressing apparatus includes a wound dressing member dimensioned for positioning relative to a wound bed. The wound dressing member including an internal vacuum reservoir and has a port in communication with the vacuum reservoir for applying subatmospheric pressure to the vacuum reservoir to facilitate removal of fluid from the wound bed. The wound dressing member includes a visual pressure indicator associated therewith for indicating a level of pressure within the vacuum reservoir. The visual pressure indicator includes color indicia having a plurality of colors corresponding to a condition of the pressure within the vacuum reservoir. The wound dressing member includes a lower absorbent member positionable adjacent the wound bed and an upper member which at least partially defines the vacuum reservoir. At least one of the top member and the lower absorbent member has the visual pressure indicator mounted thereto.

Abstract: A surgical suction device that uses positive pressure gas is shown and described. The surgical suction device includes an air amplifier. The air amplifier includes a structure defining a generally cylindrical cavity having a first opening at a first end and a second opening at a second end. The cylindrical cavity is defined by an inner wall of the cavity. The air amplifier includes an annular opening in the inner wall near the first end. The annular opening defines a jet opening adapted to allow a pressurized gas to flow out of the annular opening such that a low pressure region is produced at the first end and an amplified flow is produced at the second end. The annular opening is further configured such that the pressurized gas enters the cavity at an angle with respect to the inner wall of the cavity that is towards the second end.

Abstract: A surgical suction device that uses positive pressure gas is shown and described. The surgical suction device includes an air amplifier. The air amplifier includes a structure defining a generally cylindrical cavity having a first opening at a first end and a second opening at a second end. The cylindrical cavity is defined by an inner wall of the cavity. The air amplifier includes an annular opening in the inner wall near the first end. The annular opening defines a jet opening adapted to allow a pressurized gas to flow out of the annular opening such that a low pressure region is produced at the first end and an amplified flow is produced at the second end. The annular opening is further configured such that the pressurized gas enters the cavity at an angle with respect to the inner wall of the cavity that is towards the second end.

Abstract: A surgical suction device that uses positive pressure gas is shown and described. The surgical suction device includes an air amplifier. The air amplifier includes a structure defining a generally cylindrical cavity having a first opening at a first end and a second opening at a second end. The cylindrical cavity is defined by an inner wall of the cavity. The air amplifier includes an annular opening in the inner wall near the first end. The annular opening defines a jet opening adapted to allow a pressurized gas to flow out of the annular opening such that a low pressure region is produced at the first end and an amplified flow is produced at the second end. The annular opening is further configured such that the pressurized gas enters the cavity at an angle with respect to the inner wall of the cavity that is towards the second end.

Abstract: A surgical suction device that uses positive pressure gas is shown and described. The surgical suction device includes an air amplifier. The air amplifier includes a structure defining a generally cylindrical cavity having a first opening at a first end and a second opening at a second end. The cylindrical cavity is defined by an inner wall of the cavity. The air amplifier includes an annular opening in the inner wall near the first end. The annular opening defines a jet opening adapted to allow a pressurized gas to flow out of the annular opening such that a low pressure region is produced at the first end and an amplified flow is produced at the second end. The annular opening is further configured such that the pressurized gas enters the cavity at an angle with respect to the inner wall of the cavity that is towards the second end.

Abstract: The present invention relates to a transcatheter method for providing fluid communication between two anatomical compartments. The present invention also relates to a transcatheter system comprising an intracorporeal connector for fluid communication between two anatomical compartments through at least one anatomical wall, wherein said connector is adapted to receive a flow regulating device, a connector, a flow regulating device and an insertion device.

Abstract: A fluid pump device changeable in diameter is provided. The device has a pump housing which is changeable in diameter and with a rotor which is changeable in diameter. The device has at least one delivery element for fluid, as well as a drive shaft on which the rotor is rotatably mounted. A bearing arrangement is arranged on the drive shaft or its extension, at the distal end of the drive shaft behind the rotor seen from the proximal end of the drive shaft. The bearing arrangement has struts, which elastically brace between a hub of the bearing arrangement and the pump housing.

Abstract: A medical balloon for a balloon pump is disclosed. The medical balloon has a first end and a second end and a port at one of the ends for engaging a catheter for receiving an inflation fluid into the balloon. The balloon has one or more exterior walls defining, when the balloon is inflated at substantially a standard operating pressure, a taper along at least a part of the length of the balloon. The taper has two or more consecutive tapering sections, each tapering section having a different, substantially constant, angle of tapering. The balloon is substantially asymmetrical about a mid-point between the first and second ends when inflated.

Abstract: An extracorporeal blood purification system with at least one extracorporeal blood purification apparatus, preferably dialysis machine, which is prepared to go through a centrally controlled disinfection process for a blood purification process, as well as with an internal fluid line system which is disinfected at least during the disinfection process by a disinfectant, including an internal or external disinfecting or cleaning case which is at least during the disinfection process via at least one case connection connected to the internal fluid conduit system to receive disinfectant.

Abstract: A balancing device and a method for balancing between an inflow into a blood treatment unit of a medical treatment device and an outflow out of the blood treatment unit are disclosed. The balancing device: includes a balancing unit, which has at least one exchange vessel; means for conveying fluid into and/or out of the exchange vessel and means for interrupting the inflow of fluid into the exchange vessel and/or the outflow of fluid out of the exchange vessel; and a control unit for controlling the means for conveying fluid and the means for interrupting the inflow and/or outflow of fluid by an equalization of pressure between a first work cycle and a second work cycle.

Abstract: An apparatus for performing peritoneal dialysis includes a housing; a peritoneal dialysis supply bag supported by and/or located above the housing; a first valve for controlling gravity flow of fresh peritoneal dialysis fluid from the supply bag to a patient; a second valve for controlling gravity flow of used peritoneal dialysis fluid from the patient to a drain; and a pressure sensor positioned and arranged with respect to the gravity flow of fresh peritoneal dialysis fluid or the gravity flow of used peritoneal dialysis fluid to provide a reading used to evaluate a head height pressure.

Abstract: A blood treatment filter comprising a filter element, an inlet-side flexible container and an outlet-side flexible container, an inlet port, and a tubular outlet port, further comprises: an outlet-side frame sheet disposed between the filter element and the outlet-side flexible container; a first seal portion provided by sealing at least the filter element and the outlet-side frame sheet in a belt-shaped manner; and an annular second seal portion provided to surround the first seal portion, wherein on an outlet side of the filter element, a valley portion is fanned at the first seal portion, the outlet port includes a protruding portion that protrudes to an inside of the container, and the protruding portion is provided with an opening at least a part of which overlaps with the first seal portion and which can communicate with a gap region formed by the valley portion.